Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 24, 2017
What is the competitive landscape for GENZYME CORP, and when can generic versions of GENZYME CORP drugs launch?
GENZYME CORP has five approved drugs.| Patents: | 5 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 5 |
| Drug Master File Entries: (click here to view) | 5 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
doxercalciferol | Injection | 2 mcg/mL, 1 mL in 2 mL vial | HECTOROL | 12/28/2011 |
doxercalciferol | Capsules | 1 mcg | HECTOROL | 2/12/2010 |
doxercalciferol | Capsules | 0.5 mcg and 2.5 mcg | HECTOROL | 3/25/2009 |
doxercalciferol | Injection | 2 mcg/mL, 2 mL ampules | HECTOROL | 10/15/2007 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,855,830 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | ► Subscribe | |||||||||||||
| 7,265,228 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | ► Subscribe | |||||||||||||
| 9,546,161 | Synthesis of UDP-glucose: N-acylsphingosine glucosyl transferase inhibitors | ► Subscribe | |||||||||||||
| 5,916,911 | Amino ceramide--like compounds and therapeutic methods of use | ► Subscribe | |||||||||||||
| 6,040,332 | Amino ceramide-like compounds and therapeutic methods of use | ► Subscribe | |||||||||||||
| 6,414,148 | Quinazoline derivatives and pharmaceutical compositions containing them | ► Subscribe | |||||||||||||
| 6,030,995 | Amino ceramide-like compounds and therapeutic methods of use | ► Subscribe | |||||||||||||
| 7,763,738 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | ► Subscribe | |||||||||||||
| 5,952,370 | Amino ceramide-like compounds and therapeutic methods of use | ► Subscribe | |||||||||||||
| 8,779,163 | Synthesis of UDP-Glucose: N-acylsphingosine glucosyl transferase inhibitors | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 9813354 | ► Subscribe | |||||||||||||
| Israel | 159905 | ► Subscribe | |||||||||||||
| World Intellectual Property Organization (WIPO) | 0104108 | ► Subscribe | |||||||||||||
| Poland | 190326 | ► Subscribe | |||||||||||||
| Brazil | PI0511253 | ► Subscribe | |||||||||||||
| Hungary | 9902850 | ► Subscribe | |||||||||||||
| Austria | 439841 | ► Subscribe | |||||||||||||
| Spain | 2395463 | ► Subscribe | |||||||||||||
| Japan | 2015180656 | ► Subscribe | |||||||||||||
| European Patent Office | 1753431 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 717 | Luxembourg | ► Subscribe | PRODUCT NAME: ELIGLUSTAT, EVENTUELLEMENT SOUS LA FORME D UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20150121 | ||||||||||||
| 00738 | Netherlands | ► Subscribe | PRODUCT NAME: ELIGLUSTAT, OF FYSIOLOGISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/974 20150119 | ||||||||||||
| 0543 | Netherlands | ► Subscribe | PRODUCT NAME: VANDETANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217 | ||||||||||||
| /2015 | Austria | ► Subscribe | PRODUCT NAME: ELIGLUSTAT, OPTIONAL IN DER FORM EINES PHYSIOLOGISCH AKZEPTABLEN SALZES; REGISTRATION NO/DATE: EU/1/14/974 20150119 | ||||||||||||
| 2012015 | Lithuania | ► Subscribe | PRODUCT NAME: VANDETANIBUM; REGISTRATION NO/DATE: EU/1/11/749/001, 2012 02 17 EU/1/11/749/002 20120217 | ||||||||||||
| 90028-8 | Sweden | ► Subscribe | PRODUCT NAME: VANDETANIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/11/749/001 20120217 | ||||||||||||
| 90029-3 | Sweden | ► Subscribe | PRODUCT NAME: ELIGLUSTAT, VALFRITT I FORM AV ETT FYSIOLOGISKT GODTAGBART SALT; REG. NO/DATE: EU/1/14/974 20150121 | ||||||||||||
| 12/029 | Ireland | ► Subscribe | PRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217 | ||||||||||||
| C0036 | France | ► Subscribe | PRODUCT NAME: ELIGLUSTAT,EVENTUELLEMENT SOUS FORME D'UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/14/974 20150119 | ||||||||||||
| 0150027 00161 | Estonia | ► Subscribe | PRODUCT NAME: ELIGLUSTAAT;REG NO/DATE: EU/1/14/974 21.01.2015 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,760 others who get our Drug Patent Expiration Alerts:
